Literature DB >> 19550391

Adherence remains a challenge for patients receiving growth hormone therapy.

Svante Norgren1.   

Abstract

Patients receiving growth hormone therapy have the best growth results when they have good adherence, but adherence rates are often low. Adherence has been difficult to measure and is often measured indirectly as direct methods are inconvenient, expensive or both. However, use of electronic monitors that log the dose and the time it was delivered provides a simple and reliable means of gathering data and may facilitate the discussion of adherence in the clinic. Although many factors impact on adherence, there are some 'red flags' to which a physician should be particularly alert, such as history of poor attendance at consultations. Based on the author's own clinical experience and opinion, as well as published studies, this article describes factors associated with non-adherence and how most, if not all, barriers to good adherence can be overcome by maintaining a good non-judgemental relationship with the patient, and delivering useful and clear education and training soon after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19550391

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  5 in total

1.  COMPLIA: A 12-MONTH PROSPECTIVE, MULTICENTRE, NON-INTERVENTIONAL STUDY TO EVALUATE TREATMENT ADHERENCE AND TREATMENT SATISFACTION IN A GROWTH HORMONE DEFICIENT PAEDIATRIC POPULATION TREATED WITH NUTROPINAQ® A SOMATROPIN ANALOGUE.

Authors:  C P Dumitrescu; C Procopiuc; N Dumitriu; I Micle; M Anton; A Moisuc
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

2.  Psychometric Validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB).

Authors:  Meryl Brod; Michael Højby Rasmussen; Suzanne Alolga; Jane F Beck; Donald M Bushnell; Kai Wai Lee; Aristides Maniatis
Journal:  Pharmacoecon Open       Date:  2022-10-18

3.  Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.

Authors:  Mauro Bozzola; Michel Colle; Maria Halldin-Stenlid; Sylvain Larroque; Monia Zignani
Journal:  BMC Endocr Disord       Date:  2011-02-04       Impact factor: 2.763

Review 4.  Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.

Authors:  Carlo L Acerini; David Segal; Sherwin Criseno; Kei Takasawa; Navid Nedjatian; Sebastian Röhrich; Mohamad Maghnie
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-22       Impact factor: 5.555

5.  User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.

Authors:  Maithé Tauber; Delphine Jaquet; Monique Jesuran-Perelroizen; Marc Petrus; Anne Marie Bertrand; Regis Coutant
Journal:  Patient Prefer Adherence       Date:  2013-05-24       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.